UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1009-13
Program Prior Authorization/Notification
Medication Arcalyst® (rilonacept)
P&T Approval Date 7/2011, 7/2012, 7/2013, 8/2013, 7/2014, 2/2015, 4/2016, 4/2017, 4/2018,
4/2019, 4/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Arcalyst (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-
Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome
(FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Arcalyst is
also indicated for the maintenance of remission of Deficiency of Interleukin-1 Receptor
Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg. Additionally, Arcalyst
is indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in
adult and children 12 years and older.1
2. Coverage Criteriaa:
A. Cryopyrin-Associated Periodic Syndromes (CAPS)
1. Initial Authorization
a. Arcalyst will be approved based on the following criterion:
(1) Diagnosis of Cryopyrin-Associated Periodic Syndromes (CAPS), including
Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome
(MWS)
Authorization will be issued for 12 months.
2. Reauthorization
a. Arcalyst will be approved based on the following criterion:
(1) Documentation of positive clinical response to Arcalyst therapy
Authorization will be issued for 12 months.
B. Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
1. Initial Authorization
a. Arcalyst will be approved based on the following criteria:
(1) Diagnosis of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
© 2025 UnitedHealthcare Services, Inc.
1
-AND–
(2) Disease is in remission (e.g., diary score of < 0.5 [reflecting no fever, skin rash
and bone pain], acute phase reactants [<0.5 mg/dL CRP], absence of objective
skin rash, no radiological evidence of active bone lesions)
Authorization will be issued for 12 months.
2. Reauthorization
a. Arcalyst will be approved based on the following criterion:
(1) Documentation of positive clinical response to Arcalyst therapy
Authorization will be issued for 12 months.
C. Pericarditis
1. Initial Authorization
a. Arcalyst will be approved based on the following criterion:
(1) Diagnosis of recurrent pericarditis (RP)
Authorization will be issued for 12 months.
2. Reauthorization
a. Arcalyst will be approved based on the following criterion:
(1) Documentation of positive clinical response to Arcalyst therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class
• Supply limits may be in place.
4. References:
1. Arcalyst [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; May 2021.
© 2025 UnitedHealthcare Services, Inc.
2
Program Prior Authorization/Notification - Arcalyst (rilonacept)
Change Control
7/2013 Annual review. Updated formatting. Add IL-1 agents as a requirement to
criteria. Removed age 12 from coverage criteria and added
reauthorization criteria.
8/2013 Removed IL-1 and added ‘clinical symptoms’ and ‘elevated acute phase
reactants.’
7/2014 Annual review with no change to coverage criteria.
2/2015 Annual review with no change to coverage criteria. Updated background
and references.
4/2016 Annual review. Revised criteria to only require diagnosis. Updated
background and references.
4/2017 Annual review with no change to coverage criteria. Updated references.
4/2018 Annual review with no change to coverage criteria.
4/2019 Annual review with no change to coverage criteria.
4/2020 Annual review with no change to coverage criteria.
5/2021 Annual review. Added coverage criteria for deficiency of IL-1 receptor
antagonist and recurrent pericarditis. Updated background and references.
5/2022 Annual review. Updated references.
5/2023 Annual review with no changes to coverage criteria. Added state mandate
footnote and updated reference format.
5/2024 Annual review with no change to coverage criteria.
5/2025 Annual review with no change to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
3